Product information and disease descriptionProduct descriptionProduct information
Dosage forms and strengths
5 evidence topics · 6 sources
Phase 3 dosage form: orally disintegrating tablet using Zydis technology
Strengths studied in phase 3: 100 µg, and 50 µg as a control arm in Panorama
Strengths studied in phase 2b: 25, 50, 100, and 200 µg freebase equivalent
Phase 1 bridging study: four 25-µg capsules compared with one 100-µg orally disintegrating tablet
Commercial dosage form, strengths, and package configuration
No evidence found.